Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Ligand monetizes Promacta royalties through $827mm transaction with Royalty Pharma

Executive Summary

Ligand Pharmaceuticals Inc. agreed to sell Royalty Pharma the intellectual property rights, including the royalty stream on worldwide net sales, to Promacta (eltrombopag) for $827mm in cash.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Biotechnology
    • Drug Discovery Tools
    • Transgenics
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Royalty Sale

Related Companies

UsernamePublicRestriction

Register